Video Experimental Relacionado
Updated: Sep 10, 2025
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.5K
Asociación entre el polimorfismo ABCG2 y los eventos adversos inducidos por estatinas: un metanálisis
Da Hoon Lee1, Hae Ji Shin2, Beom Yoon2
1College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.
Cardiovascular toxicology
|August 23, 2025
Resumen
La variante del gen ABCG2 rs2231142 está relacionada con un aumento de la toxicidad de las estatinas, incluidos los problemas musculares y hepáticos. Este hallazgo pone de relieve la necesidad de una medicina personalizada en el tratamiento con estatinas.
Área de la Ciencia:
- Farmacogenómica
- Investigación de las enfermedades cardiovasculares
- Metabolismo de las drogas
Sus antecedentes:
- Las estatinas son cruciales para la prevención de enfermedades cardiovasculares, pero pueden causar reacciones adversas.
- El gen del miembro 2 de la subfamilia G de la cassette de unión al ATP (ABCG2) influye en el metabolismo del fármaco.
- El papel del polimorfismo ABCG2 rs2231142 en la toxicidad de las estatinas requiere una aclaración.
Objetivo del estudio:
- Revisar y metaanalizar sistemáticamente la asociación entre el polimorfismo de ABCG2 rs2231142 y la toxicidad inducida por las estatinas.
- Para aclarar los hallazgos no concluyentes de investigaciones anteriores.
Principales métodos:
- Se realizó una búsqueda exhaustiva de la literatura que identificó siete estudios elegibles.
- Extracción rigurosa de datos y evaluación de la calidad de los estudios incluidos.
- Metaanálisis para determinar la asociación general y los coeficientes de riesgo.
Principales resultados:
- Se encontró una asociación significativa entre el polimorfismo de ABCG2 rs2231142 y el aumento de la toxicidad global inducida por las estatinas.
- Se han identificado riesgos específicos de toxicidad muscular (OR=2,6) y hepática (OR=2,7).
- El polimorfismo afecta el metabolismo y la farmacocinética de las estatinas.
Conclusiones:
- El polimorfismo ABCG2 rs2231142 es un factor de riesgo potencial para la toxicidad inducida por las estatinas.
- Los hallazgos apoyan la importancia de estrategias de tratamiento personalizadas para la terapia con estatinas.
- Se requiere una mayor investigación sobre el papel de ABCG2 en las reacciones adversas a los medicamentos.
Palabras clave:
ABCG2 y ABCG2Casete de unión de ATP miembro 2 de la subfamilia GMeta-análisisLas estatinasToxicidadMás Videos Relacionados
Videos de Conceptos Relacionados
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:19Pharmacovigilance
989
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
989
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
273
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
273
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33